Variable influence of mutational patterns in reverse-transcriptase domain on replication capacity of hepatitis B virus isolates from antiviral-experienced patients

Clinica Chimica Acta

Volumn 412, Issue 3-4, 2011, Pages 305-313

  Ji, Dong ^a   Liu, Yan ^a   Si, Lan Lan ^a   Li, Le ^a   Chen, Guo Feng ^a   Xin, Shao Jie ^a   Zhao, Jin Min ^a   Xu, Dongping ^a  

^a BEIJING 302 HOSPITAL   (China)

Author keywords

Full length cloning; Hepatitis B virus; Mutation; Real time PCR; Replication

Indexed keywords

ANTIVIRUS AGENT; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PREGENOMIC RNA; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL STRAIN HEPG2; CELL STRAIN HUH7; CLINICAL ARTICLE; CONTROLLED STUDY; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HEPATOMA CELL; HUMAN; MOLECULAR CLONING; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; SOUTHERN BLOTTING; VIRUS GENOME; VIRUS ISOLATION; VIRUS LOAD; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION; WILD TYPE;

ANTIVIRAL AGENTS; CALIBRATION; GENOME, VIRAL; GENOTYPE; HEP G2 CELLS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTRACELLULAR SPACE; MUTAGENESIS, SITE-DIRECTED; MUTATION; POLYMERASE CHAIN REACTION; PROTEIN STRUCTURE, TERTIARY; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; RNA-DIRECTED DNA POLYMERASE; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 78650231104     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.10.028     Document Type: Article

References (47)

1. Andersson K.L., Chung R.T. Monitoring during and after antiviral therapy for hepatitis B. Hepatology 2009, 49:S166-S173.
2. Liang T.J. Hepatitis B: the virus and disease. Hepatology 2009, 49:S13-S21.
3. Di Marco V., Craxi A. Chronic hepatitis B: who to treat and which choice of treatment?. Expert Rev Anti Infect Ther 2009, 7:281-291.
4. Gish R.G. Hepatitis B treatment: current best practices, avoiding resistance. Cleve Clin J Med 2009, 76(Suppl 3):S14-S19.
5. Pawlotsky J.M., Dusheiko G., Hatzakis A., et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008, 134:405-415.
6. Allen M.I., Deslauriers M., Andrews C.W., et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998, 27:1670-1677.
7. Angus P., Vaughan R., Xiong S., et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125:292-297.
8. Borroto-Esoda K., Miller M.D., Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol 2007, 47:492-498.
9. Wang Y.Z., Xiao J.H., Ruan L.H., et al. Detection of the rtA181V/T and rtN236T mutations associated with resistance to adefovir dipivoxil using a ligase detection reaction assay. Clin Chim Acta 2009, 408:70-74.
10. Tenney D.J., Levine S.M., Rose R.E., et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004, 48:3498-3507.
11. Tenney D.J., Rose R.E., Baldick C.J., et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007, 51:902-911.
12. Baldick C.J., Eggers B.J., Fang J., et al. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol 2008, 48:895-902.
13. Lai C.L., Leung N., Teo E.K., et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005, 129:528-536.
14. Ghany M.G., Doo E.C. Antiviral resistance and hepatitis B therapy. Hepatology 2009, 49:S174-S184.
15. Warner N., Locarnini S., Kuiper M., et al. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother 2007, 51:2285-2292.
16. Delaney WEt, Yang H., Westland C.E., et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003, 77:11833-11841.
17. Mazet-Wagner A.A., Baclet M.C., Loustaud-Ratti V., Denis F., Alain S. Real-time PCR quantitation of hepatitis B virus total DNA and covalently closed circular DNA in peripheral blood mononuclear cells from hepatitis B virus-infected patients. J Virol Meth 2006, 138:70-79.
18. Zoulim F., Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009, 137:1593-1608.
19. Schildgen O., Sirma H., Funk A., et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006, 354:1807-1812.
20. Qi X., Xiong S., Yang H., Miller M., Delaney W.E. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007, 12:355-362.
21. Thibault V., Aubron-Olivier C., Agut H., Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 2002, 16:131-133.
22. Fang J., Wichroski M.J., Levine S.M., et al. Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates. Antimicrob Agents Chemother 2009, 53:2762-2772.
23. Sayan M., Akhan S.C., Meric M. Naturally occurring amino-acid substitutions to nucleos(t)ide analogues in treatment naive Turkish patients with chronic hepatitis B. J Viral Hepat 2009, 17:23-27.
24. Fung S., Wong F., Mazzulli T., Popovic V. Pre-existing antiviral-resistant mutation may be associated with primary non-response to lamivudine among treatment-naïve chronic hepatitis B patients. Hepatology 2009, 50:523A.
25. Hayashi K., Katano Y., Ishigami M., et al. Prevalence and clinical characterization of patients with acute hepatitis B induced by lamivudine-resistant strains. J Gastroenterol Hepatol 2010, 25:745-749.
26. Zoulim F. In vitro models for studying hepatitis B virus drug resistance. Semin Liver Dis 2006, 26:171-180.
27. Günther S., Li B.C., Miska S., Krüger D.H., Meisel H., Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995, 69:5437-5444.
28. Durantel D., Brunelle M.N., Gros E., et al. Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. J Clin Virol 2005, 34(Suppl 1):S34-S43.
29. Chinese Society of Infectious Diseases and Parasitology, Chinese Society of Hepatology Management scheme of diagnostic and therapy criteria of viral hepatitis. Zhonghua Gan Zang Bing Za Zhi (Chinese J Hepatol) 2000, 6:324-329.
30. Xu D., Fu J., Jin L., et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006, 177:739-747.
31. Ren X., Xu Z., Liu Y., et al. Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. J Viral Hepat 2010, 17:887-895.
32. Liu Y., Zhong Y., Zou Z., et al. Features and clinical implications of hepatitis B virus genotypes and mutations in basal core promoter/precore region in 507 Chinese patients with acute and chronic hepatitis B. J Clin Virol 2010, 47:243-247.
33. Hirsch R., Colgrove R., Ganem D. Replication of duck hepatitis B virus in two differentiated human hepatoma cell lines after transfection with cloned viral DNA. Virology 1988, 167:136-142.
34. Payungporn S., Tangkijvanich P., Jantaradsamee P., Theamboonlers A., Poovorawan Y. Simultaneous quantitation and genotyping of hepatitis B virus by real-time PCR and melting curve analysis. J Virol Meth 2004, 120:131-140.
35. Weinberger K.M., Wiedenmann E., Bohm S., Jilg W. Sensitive and accurate quantitation of hepatitis B virus DNA using a kinetic fluorescence detection system (TaqMan PCR). J Virol Meth 2000, 85:75-82.
36. Pellicelli A.M., Barbaro G., Francavilla R., et al. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study. Clin Ther 2008, 30:317-323.
37. Chotiyaputta W., Lok A.S. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol 2009, 6:453-462.
38. Jammeh S., Tavner F., Watson R., Thomas H.C., Karayiannis P. Effect of basal core promoter and pre-core mutations on hepatitis B virus replication. J Gen Virol 2008, 89:901-909.
39. Miyagawa M., Minami M., Fujii K., et al. Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab. J Med Virol 2008, 80:2069-2078.
40. Santantonio T., Fasano M., Durantel S., et al. Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B. Antivir Ther 2009, 14:557-565.
41. Domiati-Saad R., Scheuermann R.H. Nucleic acid testing for viral burden and viral genotyping. Clin Chim Acta 2006, 363:197-205.
42. Torresi J., Earnest-Silveira L., Civitico G., et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002, 299:88-99.
43. Villet S., Pichoud C., Villeneuve J.P., Trepo C., Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006, 131:1253-1261.
44. Ciancio A., Smedile A., Rizzetto M., Lagget M., Gerin J., Korba B. Identification of HBV DNA sequences that are predictive of response to lamivudine therapy. Hepatology 2004, 39:64-73.
45. Karatayli E., Karayalçin S., Karaaslan H., et al. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther 2007, 12:761-768.
46. Amini-Bavil-Olyaee S., Herbers U., Mohebbi S.R., et al. Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome. J Hepatol 2009, 51:647-654.
47. Villet S., Billioud G., Pichoud C., et al. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. Gastroenterology 2009, 136:168-176.